Your session is about to expire
← Back to Search
Cancer Vaccine
Pneumonia Vaccine for People with HIV (VIVID Trial)
Phase 4
Recruiting
Research Sponsored by Hennepin Healthcare Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days and 2 years
Awards & highlights
Summary
This trial will monitor how well a pneumonia vaccine works over time in people with HIV and how age affects its effectiveness.
Who is the study for?
This trial is for aging individuals living with HIV. It's designed to understand how well and for how long a pneumococcal vaccine (PCV20) can protect them against infections.
What is being tested?
The study focuses on the immune response to the PCV20 vaccine in people with HIV as they age, tracking how effective the vaccine is over time in providing protection.
What are the potential side effects?
Possible side effects of PCV20 may include pain at injection site, fatigue, headache, muscle pain, joint pain, decreased appetite, chills or rash.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 days and 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days and 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Primary objective
Secondary study objectives
Secondary objective
Trial Design
1Treatment groups
Experimental Treatment
Group I: Pneumococcal VaccinationExperimental Treatment1 Intervention
All participants will receive a pneumococcal vaccine.
Find a Location
Who is running the clinical trial?
Hennepin Healthcare Research InstituteLead Sponsor
91 Previous Clinical Trials
77,177 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger